Comorbid anxiety is common in depressive Comorbid anxiety is common in depressive disorders, both in middle and in later life. disorders, both in middle and in later life. In community samples of younger adults In community samples of younger adults with depression, the point prevalence of with depression, the point prevalence of comorbid anxiety disorders ranged from comorbid anxiety disorders ranged from 33% (Flint, 1994) to 51% (Kessler 33% (Flint, 1994) to 51% (Kessler et al et al, , 1996) , with a 46% point prevalence in a 1996), with a 46% point prevalence in a clinical sample (Fava clinical sample (Fava et al et al, 2004) . In com-, 2004) . In community samples of older adults with late-munity samples of older adults with latelife depression, the point prevalence of life depression, the point prevalence of comorbid anxiety disorders ranged from comorbid anxiety disorders ranged from 26% (Ben-Arie 26% (Ben-Arie et al et al, 1987) to 48% , 1987) to 48% (Beekman (Beekman et al et al, 2000) . In clinical samples , 2000) . In clinical samples of older patients with late-life depression, of older patients with late-life depression, comorbid anxiety disorders were diagnosed comorbid anxiety disorders were diagnosed in 3% to 65% (Parmalee in 3% to 65% (Parmalee et al et al, 1993; , 1993; Mulsant Mulsant et al et al, 1996; Lenze , 1996; Lenze et al et al, 2000) . , 2000) . Beyond the high rates of coexistence, Beyond the high rates of coexistence, comorbid anxiety has been often cited as comorbid anxiety has been often cited as a clinically relevant problem owing to its a clinically relevant problem owing to its impact on acute treatment response in impact on acute treatment response in late-life depression. Thus, several studies late-life depression. Thus, several studies have found that greater severity of anxiety have found that greater severity of anxiety symptoms is associated with an increased symptoms is associated with an increased risk of withdrawal from treatment risk of withdrawal from treatment (Fawcett, 1997; Flint & Rifat, 1997 (Fawcett, 1997 Flint & Rifat, 1997a a), a ), a decreased response to acute antidepressant decreased response to acute antidepressant treatment (Fawcett, 1997; Flint & Rifat, treatment (Fawcett, 1997; Flint & Rifat, 1997 1997a Steffens & McQuoid, 2005) , and a ; Steffens & McQuoid, 2005) , and a longer time to both response (Mulsant longer time to both response (Mulsant et et al al, 1996; Dew , 1996; Dew et al et al, 1997; Lenze , 1997; Lenze et al et al, , 2003) and remission (Clayton 2003) and remission (Clayton et al et al, 1991; , 1991; Alexopoulos Alexopoulos et al et al, 2005) . , 2005) . Although the impact of anxiety on re-Although the impact of anxiety on response and recurrence of major depression sponse and recurrence of major depression has been previously studied extensively in has been previously studied extensively in general adult populations, its relevance to general adult populations, its relevance to long-term treatment response in late-life long-term treatment response in late-life depression has received much less attention depression has received much less attention (Lebowitz (Lebowitz et al et al, 1997; Charney , 1997; Charney et al et al, 2003) , 2003) and has not been examined in a controlled and has not been examined in a controlled maintenance trial. Maintenance outcomes maintenance trial. Maintenance outcomes in late-life depression and the factors that in late-life depression and the factors that moderate those outcomes are critical, given moderate those outcomes are critical, given the brittle nature of response in this age the brittle nature of response in this age group (Reynolds & Lebowitz, 1999; group (Reynolds & Lebowitz, 1999; Reynolds Reynolds et al et al, 2006) . To our knowledge, , 2006) . To our knowledge, the only published data addressing these the only published data addressing these long-term outcomes were obtained during long-term outcomes were obtained during a 2-year naturalistic follow-up study. In this a 2-year naturalistic follow-up study. In this uncontrolled study, pre-treatment anxiety uncontrolled study, pre-treatment anxiety symptoms were not related to time to recur-symptoms were not related to time to recurrence during 2 years of open pharmaco-rence during 2 years of open pharmacotherapy trial with nortriptyline (Flint & therapy trial with nortriptyline (Flint & Rifat, 1997 Rifat, 1997b . ).
Thus, given the high recurrence rate of Thus, given the high recurrence rate of late-life depression (Zis late-life depression ) and the increased morbidity and mortality risks the increased morbidity and mortality risks associated with this disorder (Ganguli associated with this disorder (Ganguli et al et al, , 1993 (Ganguli et al et al, , , 2002 Reynolds 1993 Reynolds , 2002 Reynolds et al et al, 1994) , as well , 1994), as well as the lack of controlled data regarding as the lack of controlled data regarding the impact of pre-treatment anxiety on its the impact of pre-treatment anxiety on its long-term treatment, further examination long-term treatment, further examination of anxiety as a predictor not only of of anxiety as a predictor not only of response but of recurrence would greatly response but of recurrence would greatly benefit clinicians in planning treatment. benefit clinicians in planning treatment. Accordingly, we conducted an analysis to Accordingly, we conducted an analysis to assess whether pre-treatment comorbid assess whether pre-treatment comorbid anxiety predicts treatment outcomes during anxiety predicts treatment outcomes during both acute and maintenance treatment of both acute and maintenance treatment of major depression in old age. Our hypoth-major depression in old age. Our hypothesis was that greater pre-treatment severity esis was that greater pre-treatment severity of anxiety symptoms would predict poor of anxiety symptoms would predict poor treatment outcome, including both a longer treatment outcome, including both a longer time to response during acute treatment, time to response during acute treatment, and an increased rate of -and shorter time and an increased rate of -and shorter time to -recurrence during maintenance treat-to -recurrence during maintenance treatment. ment.
METHOD METHOD
Data for this analysis were provided by the Data for this analysis were provided by the second study of Maintenance Therapies in second study of Maintenance , 1984) until they achieved response (defined 1984) until they achieved response (defined as a HRSD score of 10 or less for three as a HRSD score of 10 or less for three consecutive weeks). Pharmacotherapy con-consecutive weeks). Pharmacotherapy consisted of paroxetine started at 10 mg/day sisted of paroxetine started at 10 mg/day and titrated as necessary up to a maximum and titrated as necessary up to a maximum of 40 mg/day. Adjunctive pharmacotherapy of 40 mg/day. Adjunctive pharmacotherapy with bupropion, nortriptyline or lithium with bupropion, nortriptyline or lithium was used when required to achieve response was used when required to achieve response ( (n n¼69). Adjunctive lorazepam (0.5-2 mg/ 69). Adjunctive lorazepam (0.5-2 mg/ day) was also used in 65 patients. day) was also used in 65 patients.
Patients who responded to acute treat-Patients who responded to acute treatment entered 16 weeks of continuation ment entered 16 weeks of continuation treatment to stabilise their response; they treatment to stabilise their response; they received the same pharmacotherapy and received the same pharmacotherapy and interpersonal psychotherapy every 2 weeks. interpersonal psychotherapy every 2 weeks. Patients who maintained response during Patients who maintained response during continuation treatment were then randomly continuation treatment were then randomly assigned to one of four maintenance treat-assigned to one of four maintenance treatments: ments: Patients randomised to pharmacother-Patients randomised to pharmacotherapy received paroxetine (with adjunctive apy received paroxetine (with adjunctive medication if required) for the remainder medication if required) for the remainder of their study participation. Patients ran-of their study participation. Patients randomised to receive placebo had paroxetine domised to receive placebo had paroxetine (and adjunctive medication) slowly tapered (and adjunctive medication) slowly tapered over 6 weeks under double-blind condi-over 6 weeks under double-blind conditions. All patients were allowed to remain tions. All patients were allowed to remain on a stable dosage of lorazepam if it had on a stable dosage of lorazepam if it had been required during the acute or continua-been required during the acute or continuation treatment phases. Patients remained in tion treatment phases. Patients remained in maintenance therapy for 2 years or until maintenance therapy for 2 years or until recurrence of a major depressive episode. recurrence of a major depressive episode. Recurrence required a HRSD score of 15 Recurrence required a HRSD score of 15 or over, meeting DSM-IV criteria (Ameri-or over, meeting DSM-IV criteria (American Psychiatric Association, 1994) for a can Psychiatric Association, 1994) for a major depressive episode during a SCID in-major depressive episode during a SCID interview, and confirmation of the diagnosis terview, and confirmation of the diagnosis by an independent geriatric psychiatrist. by an independent geriatric psychiatrist. Assessors were unaware of treatment as-Assessors were unaware of treatment assignment. All patients provided written in-signment. All patients provided written informed consent. For this data analysis we formed consent. For this data analysis we collapsed the interpersonal psychotherapy collapsed the interpersonal psychotherapy and non-psychotherapy groups because this and non-psychotherapy groups because this therapy was not shown to prevent recur-therapy was not shown to prevent recurrence in the primary outcome analysis, rence in the primary outcome analysis, whereas paroxetine was (Reynolds whereas paroxetine was (Reynolds et al et al, , 2006 (Reynolds et al et al, , ). 2006 .
Symptoms of anxiety were measured Symptoms of anxiety were measured using the self-report anxiety scale from the using the self-report anxiety scale from the Brief Symptom Inventory (BSI; Derogatis Brief Symptom Inventory (BSI; Derogatis & Melisaratos, 1983) . The BSI is a vali-& Melisaratos, 1983). The BSI is a validated self-report scale developed from the dated self-report scale developed from the Symptom Checklist 90 -Revised (SCL-Symptom Checklist 90 -Revised (SCL-90-R; Derogatis, 1983) with strong test-90-R; Derogatis, 1983) with strong testretest and internal consistency reliabilities. retest and internal consistency reliabilities. Factor analytic studies of the internal Factor analytic studies of the internal structure of the scale have demonstrated structure of the scale have demonstrated its construct validity (Derogatis, 1983) . its construct validity (Derogatis, 1983) . The anxiety sub-scale consists of six items: The anxiety sub-scale consists of six items: 'nervousness or shakiness inside', 'suddenly 'nervousness or shakiness inside', 'suddenly scared for no reason', 'feeling fearful', 'feel-scared for no reason', 'feeling fearful', 'feeling tense or keyed up', 'spells of terror or ing tense or keyed up', 'spells of terror or panic' and 'feeling so restless you couldn't panic' and 'feeling so restless you couldn't sit still'. Each item is rated on a five-point sit still'. Each item is rated on a five-point scale (0 symptom not present, 4 extremely scale (0 symptom not present, 4 extremely severe). We used both a categorical and a severe). We used both a categorical and a continuous form of the BSI anxiety mea-continuous form of the BSI anxiety measure. We analysed BSI scores (Cronbach's sure. We analysed BSI scores (Cronbach's a a¼0.84 for the present sample) on a conti-0.84 for the present sample) on a continuum and also we also dichotomised those nuum and also we also dichotomised those with higher with higher v. v. lower anxiety by using a lower anxiety by using a median split (median value for the sample median split (median value for the sample 1.0). We present in this paper the results 1.0). We present in this paper the results based on the categorical approach because based on the categorical approach because it has more relevance to the categorical de-it has more relevance to the categorical decisions clinicians are faced with in their cisions clinicians are faced with in their practice. practice.
The analyses included data on 181 per-The analyses included data on 181 persons who participated in the acute treat-sons who participated in the acute treatment phase. Of these, 116 maintained ment phase. Of these, 116 maintained response during continuation treatment response during continuation treatment and were randomly assigned to mainte-and were randomly assigned to maintenance treatment. Pre-treatment BSI scores nance treatment. Pre-treatment BSI scores were available on 170 participants entering were available on 170 participants entering the acute phase. Of these, 109 participated in the acute phase. Of these, 109 participated in randomly assigned maintenance treatment. randomly assigned maintenance treatment.
Statistical analysis Statistical analysis
We used Kaplan-Meier survival analysis to We used Kaplan-Meier survival analysis to assess the effect of pre-treatment anxiety assess the effect of pre-treatment anxiety symptoms (BSI scores) on time to response. symptoms (BSI scores) on time to response. In order to analyse the influence of loraze-In order to analyse the influence of lorazepam on time to response (Buysse pam on time to response (Buysse et al et al, , 1997), we compared the time to response 1997), we compared the time to response in the group receiving lorazepam in the group receiving lorazepam v.
v. the the group not receiving lorazepam. Further, group not receiving lorazepam. Further, we stratified the sample based on presence we stratified the sample based on presence or absence of lorazepam use. In order to or absence of lorazepam use. In order to control for other potential confounders, control for other potential confounders, we subsequently fitted Cox proportional we subsequently fitted Cox proportional hazards models for each outcome, stratify-hazards models for each outcome, stratifying on severity of depression to estimate ing on severity of depression to estimate the unique effects of anxiety on acute treat-the unique effects of anxiety on acute treatment outcomes. We controlled for baseline ment outcomes. We controlled for baseline depression severity as measured by the depression severity as measured by the HRSD scores, with the four anxiety-related HRSD scores, with the four anxiety-related items (9, 10, 11 and 15) removed (Dew items (9, 10, 11 and 15) , 2007) . To assess the effect of comorbid sympto-To assess the effect of comorbid symptomatic anxiety on time to recurrence during matic anxiety on time to recurrence during maintenance treatment, we stratified the sam-maintenance treatment, we stratified the sample based on randomisation to paroxetine or ple based on randomisation to paroxetine or placebo and performed Kaplan-Meier ana-placebo and performed Kaplan-Meier analyses in four groups: pharmacotherapy with lyses in four groups: pharmacotherapy with lower BSI scores ( lower BSI scores (n n¼35); pharmacotherapy 35); pharmacotherapy with higher BSI scores ( with higher BSI scores (n n¼23); placebo with 23); placebo with lower BSI scores ( lower BSI scores (n n¼31); and placebo with 31); and placebo with higher BSI scores ( higher BSI scores (n n¼20). 20).
RESULTS RESULTS
Participants' baseline demographic and Participants' baseline demographic and clinical characteristics are presented in clinical characteristics are presented in Table 1 . (Table 2) . Patients with higher BSI scores had a median time to response BSI scores had a median time to response significantly longer than those with lower significantly longer than those with lower scores scores ( Fig. 1 ): 11.0 (95% CI 7.7-13.9) ( Fig. 1 ): 11.0 (95% CI 7.7-13.9) v. v. 6.7 (95% 6.7 (95% CI 5.9-7.9) weeks (Wilcoxon CI 5.9-7.9) weeks (Wilcoxon w w 2 2 ¼6.26, d.f. 6.26, d.f.¼1, 1, P P¼0.01). 0.01).
Effects of adjunctive lorazepam Effects of adjunctive lorazepam
Patients who received adjunctive lorazepam Patients who received adjunctive lorazepam ( (n n¼65) had a median time to response sig-65) had a median time to response significantly longer than those who did not nificantly longer than those who did not ( (n n¼120): 12.4 weeks (95% CI 8.4-14.7) 120): 12.4 weeks (95% CI 8.4-14.7) v. v. 6.9 weeks (95% CI 5.6-7.9); Wilcoxon 6.9 weeks (95% CI 5.6-7.9); Wilcoxon w w 2 2 ¼16. 45. However, as would be expected, lorazepam use was cor-would be expected, lorazepam use was correlated with higher BSI scores (phi related with higher BSI scores (phi¼0.31). 0.31). Therefore, we analysed Therefore, we analysed post hoc post hoc the time the time to response separately in patients who re-to response separately in patients who received and did not receive lorazepam, con-ceived and did not receive lorazepam, contrasting those with higher and lower BSI trasting those with higher and lower BSI scores. Among patients who received lora-scores. Among patients who received lorazepam, those with higher BSI scores had a zepam, those with higher BSI scores had a median time to response significantly long-median time to response significantly longer than those with lower scores: 13.9 weeks er than those with lower scores: 13.9 weeks (95% CI 11.0-17.1) (95% CI 11.0-17.1) v. v. 7.9 weeks (95% CI 7.9 weeks (95% CI 5.9-13.6); Wilcoxon 5.9-13.6); 22-3.72 ). Time to recurrence from randomis-3.72). Time to recurrence from randomisation (Fig. 2) differed across the four ation (Fig. 2) differed across the four groups, with the higher BSI group having groups, with the higher BSI group having a shorter time to recurrence (log-rank a shorter time to recurrence (log-rank w w 2 2 ¼ 15.00, d.f. 15.00, d.f.¼3, 3, P P¼0.002). Recurrence rates 0.002). Recurrence rates (adjusting for censoring) were 29% (phar-(adjusting for censoring) were 29% (pharmacotherapy with lower BSI scores), 58% macotherapy with lower BSI scores), 58% (pharmacotherapy with higher BSI scores), (pharmacotherapy with higher BSI scores), 54% (placebo with lower BSI scores) and 54% (placebo with lower BSI scores) and 81% (placebo with higher BSI scores). 81% (placebo with higher BSI scores). Among patients receiving pharmacother-Among patients receiving pharmacotherapy, time to recurrence was significantly apy, time to recurrence was significantly shorter for those with higher BSI scores shorter for those with higher BSI scores than for those with lower scores (log-rank than for those with lower scores (log-rank w w 2 2 ¼5.66, d.f. 5.66, d.f.¼1, 1, P P¼0.02). Among patients 0.02). Among patients given placebo, time to recurrence did not given placebo, time to recurrence did not differ significantly between those with differ significantly between those with higher or lower BSI scores (log-rank higher or lower BSI scores (log-rank w w 2 2 ¼2.54, d.f. 2.54, d.f.¼1, 1, P P¼0.11). Among patients 0.11). Among patients with higher BSI scores, time to recurrence with higher BSI scores, time to recurrence did not differ between those given placebo did not differ between those given placebo or paroxetine (log-rank or paroxetine (log-rank w w 2 2 ¼1.95, d.f. 1.95, d.f.¼1, 1, P P¼0.16). Among patients with lower BSI 0.16). Among patients with lower BSI scores, time to recurrence was significantly scores, time to recurrence was significantly shorter for those in the placebo group than shorter for those in the placebo group than for those taking paroxetine (log-rank for those taking paroxetine (log-rank w w 2 2 ¼ 5.28, d.f. 5.28, d.f.¼1, 1, P P¼0.02). 0.02). Because these findings suggested a Because these findings suggested a moderator effect of anxiety, a separate moderator effect of anxiety, a separate Cox regression examined the possible Cox regression examined the possible moderator effect of anxiety (measured by moderator effect of anxiety (measured by BSI) on maintenance treatment outcomes, BSI) on maintenance treatment outcomes, by analysing the interaction between BSI by analysing the interaction between BSI scores and pharmacotherapy. The results scores and pharmacotherapy. The results did not confirm a moderator effect did not confirm a moderator effect ( (w w 2 2 ¼0.49, d.f. 0.49, d.f.¼1, 1, P P¼0.48). The power to 0.48). The power to detect a moderator effect was low (0.22) detect a moderator effect was low (0.22) and the hazard ratio for the interaction and the hazard ratio for the interaction was 1.5 (95% CI 0.48-4.68). was 1.5 (95% CI 0.48-4.68).
We repeated the analysis for both acute We repeated the analysis for both acute and maintenance phases using BSI score as and maintenance phases using BSI score as a continuous measure, with similar results a continuous measure, with similar results (further details available from the authors). (further details available from the authors).
DISCUSSION DISCUSSION

Summary of findings Summary of findings
Our study is the first to show that high pre-Our study is the first to show that high pretreatment levels of anxiety symptoms in-treatment levels of anxiety symptoms increase not only the risk of non-response in crease not only the risk of non-response in acute treatment of late-life depression but acute treatment of late-life depression but also the risk of recurrence of the disorder also the risk of recurrence of the disorder 3 4 6 3 4 6 AUTHOR'S PROOF AUTHOR'S PROOF in the first 2 years after response to treat-in the first 2 years after response to treatment. In other words, elderly patients who ment. In other words, elderly patients who start treatment with more severe anxiety start treatment with more severe anxiety have both a poorer acute response and a have both a poorer acute response and a more brittle long-term response to pharma-more brittle long-term response to pharmacotherapy. These results demonstrate a cotherapy. These results demonstrate a strong negative impact of anxiety symp-strong negative impact of anxiety symptoms on short-and long-term outcomes of toms on short-and long-term outcomes of depression in old age, even with optimal depression in old age, even with optimal treatment. These findings for acute treat-treatment. These findings for acute treatment effects confirm previous reports ment effects confirm previous reports (Mulsant (Mulsant et al et al, 1996; Dew , 1996; Dew et al et al, 1997; Flint , 1997; Flint & Rifat, 1997 & Rifat, 1997a a) that greater pre-treatment ) that greater pre-treatment anxiety is associated with poorer response anxiety is associated with poorer response during acute treatment of late-life depres-during acute treatment of late-life depression. We also found that these comorbid sion. We also found that these comorbid anxiety symptoms increase the risk of anxiety symptoms increase the risk of recurrence. To our knowledge, only one recurrence. To our knowledge, only one previous uncontrolled follow-up study has previous uncontrolled follow-up study has examined the impact of comorbid anxiety examined the impact of comorbid anxiety on long-term outcome of late-life depression: on long-term outcome of late-life depression: in this naturalistic study, pre-treatment in this naturalistic study, pre-treatment anxiety did not predict time to recurrence anxiety did not predict time to recurrence (Flint & Rifat, 1997 (Flint & Rifat, 1997b . ).
We found that patients with higher BSI We found that patients with higher BSI scores and adjunctive lorazepam treatment scores and adjunctive lorazepam treatment had increased time to response. The use of had increased time to response. The use of lorazepam lorazepam per se per se probably did not prolong probably did not prolong time to response, because patients receiving time to response, because patients receiving adjunctive lorazepam but having lower BSI adjunctive lorazepam but having lower BSI scores had similar time to response as scores had similar time to response as patients not receiving adjunctive lorazepam. patients not receiving adjunctive lorazepam. This observation is consistent with our This observation is consistent with our previous study (Buysse previous study (Buysse et al et al, 1997) , which , 1997), which reported that adjunctive lorazepam did reported that adjunctive lorazepam did not slow the antidepressant response in not slow the antidepressant response in elderly patients with depression. However, elderly patients with depression. However, patients with higher BSI scores not receiv-patients with higher BSI scores not receiving adjunctive lorazepam had a shorter ing adjunctive lorazepam had a shorter time to response than those with higher time to response than those with higher scores who received lorazepam. One poss-scores who received lorazepam. One possible explanation that deserves further ex-ible explanation that deserves further exploration is that the patients with higher ploration is that the patients with higher BSI scores who needed adjunctive loraze-BSI scores who needed adjunctive lorazepam differed clinically from the patients pam differed clinically from the patients with higher scores who did not need ad-with higher scores who did not need adjunctive lorazepam. This difference might junctive lorazepam. This difference might be related to a higher preponderance of be related to a higher preponderance of symptoms of general anxiety disorder in symptoms of general anxiety disorder in the group who needed adjunctive loraze-the group who needed adjunctive lorazepam, as general anxiety disorder more often pam, as general anxiety disorder more often than other anxiety disorders is associated than other anxiety disorders is associated with worse outcomes (Beekman with worse outcomes (Beekman et al et al, , 2000; Lenze 2000; Lenze et al et al, 2000) . , 2000).
Strengths and limitations Strengths and limitations
Our study was limited in its power to detect Our study was limited in its power to detect a moderator effect -that is, interactions a moderator effect -that is, interactions between treatment and coexisting anxiety. between treatment and coexisting anxiety. We were able to detect main effects of We were able to detect main effects of pharmacotherapy and of anxiety on recur-pharmacotherapy and of anxiety on recurrence, but the study lacked sufficient power rence, but the study lacked sufficient power to detect interaction between pharma-to detect interaction between pharmacotherapy and anxiety. cotherapy and anxiety. This study is the first randomised This study is the first randomised controlled trial to demonstrate the limited controlled trial to demonstrate the limited efficacy of standard pharmacotherapy in efficacy of standard pharmacotherapy in late-life depression with coexisting anxiety late-life depression with coexisting anxiety to make and keep patients well. It is to make and keep patients well. It is important to emphasise that patients important to emphasise that patients treated in this study received intensive man-treated in this study received intensive management, with clinicians and psychiatrists agement, with clinicians and psychiatrists reviewing cases weekly and refining reviewing cases weekly and refining treatment plans to minimise attrition and treatment plans to minimise attrition and maximise response. Also, adjunctive phar-maximise response. Also, adjunctive pharmacotherapeutic strategies, which were macotherapeutic strategies, which were instrumental in many patients achieving instrumental in many patients achieving response and which were continued during response and which were continued during the maintenance phase, were still not the maintenance phase, were still not enough to protect most patients with co-enough to protect most patients with comorbid anxiety from recurrence of depres-morbid anxiety from recurrence of depression. Even under these intensive treatment sion. Even under these intensive treatment conditions, which go well beyond regular conditions, which go well beyond regular clinical care, comorbid anxiety had a clinical care, comorbid anxiety had a prominent negative effect on acute and prominent negative effect on acute and long-term outcomes. long-term outcomes.
Future directions Future directions
Overall, our findings suggest limited Overall, our findings suggest limited efficacy of current medications with regard efficacy of current medications with regard to mitigating the impact of comorbid to mitigating the impact of comorbid anxiety on response and recurrence, even anxiety on response and recurrence, even though selective serotonin reuptake inhibi-though selective serotonin reuptake inhibitors (such as paroxetine, used in this study) tors (such as paroxetine, used in this study) are indicated for the treatment of both are indicated for the treatment of both anxiety and depression. It is also worth anxiety and depression. It is also worth noting that adding lorazepam to paroxetine noting that adding lorazepam to paroxetine in cases of patients with higher anxiety did in cases of patients with higher anxiety did not improve outcomes. Alternative treat-not improve outcomes. Alternative treatment options should be considered for these ment options should be considered for these patients. Given the detrimental effect of an-patients. Given the detrimental effect of anxiety on long-term course of depression and xiety on long-term course of depression and the limited benefit demonstrated here even the limited benefit demonstrated here even with optimal treatment, clinicians are left with optimal treatment, clinicians are left with the challenge of deciding what they with the challenge of deciding what they can do to improve outcome in this group can do to improve outcome in this group of patients (Tyrer of patients (Tyrer et al et al, 2004) . Expert , 2004) . Expert consensus guidelines (Alexopoulos consensus guidelines (Alexopoulos et al et al, , 2001 ) recommend maximising the dosage 2001) recommend maximising the dosage of antidepressant. It is possible that dosages of antidepressant. It is possible that dosages of paroxetine higher than those used in this of paroxetine higher than those used in this study would have yielded better outcomes in study would have yielded better outcomes in anxious patients (Baldwin & Polkinghorn, anxious patients (Baldwin & Polkinghorn, 2005) . However, older adults may not 2005) . However, older adults may not 3 4 7 3 4 7 AUTHOR'S PROOF AUTHOR'S PROOF tolerate high doses of antidepressants, given tolerate high doses of antidepressants, given the frequent medical comorbidity and sensi-the frequent medical comorbidity and sensitivity to medications' side-effects in this tivity to medications' side-effects in this population. Further research involving population. Further research involving possible pharmacological alternatives such possible pharmacological alternatives such as adjunctive use of second-generation anti-as adjunctive use of second-generation antipsychotic agents (Adson psychotic agents (Adson et al et al, 2005; , 2005a a) as well as ) as well as learning-based psychotherapies such as learning-based psychotherapies such as problem-solving therapy and cognitive-problem-solving therapy and cognitivebehavioural therapy (Stanley behavioural therapy (Stanley et al et al, 2003; , 2003; , 2005b ) is warranted. ) is warranted. In conclusion, replicating and extend-In conclusion, replicating and extending the results of previous studies, our find-ing the results of previous studies, our findings indicate a need for active identification ings indicate a need for active identification and aggressive treatment of anxiety symp-and aggressive treatment of anxiety symptoms in late-life depression, as well as the toms in late-life depression, as well as the need for further research to identify optimal need for further research to identify optimal treatment. In order to improve outcomes in treatment. In order to improve outcomes in elderly patients with anxious depression, elderly patients with anxious depression, we need to develop and test treatment we need to develop and test treatment algorithms that would involve both psy-algorithms that would involve both psychosocial and pharmacological alternative chosocial and pharmacological alternative treatments. treatments. (2005) Rates and predictors of mortality in an aging, rural, Rates and predictors of mortality in an aging, rural, community-based cohort: the role of depression. community-based cohort: the role of depression.
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